Shutterstock

A group of Johns Hopkins University scientists wrote in a recent journal article that psilocybin, the active ingredient in psychedelic magic mushrooms, has a low risk of harm and a high potential as a therapeutic drug. There’s been a resurgence of interest lately in psychedelics’ therapeutic potential for a variety of mental health applications, from depression to anxiety. Pending results from several ongoing clinical trials, the researchers called for psilocybin to be placed in the most lenient category by the Drug Enforcement Administration — alongside CBD, which was rescheduled last month, and cough syrup.

It’s not every day that a team of top-notch scientists calls for an illegal psychedelic drug to be made available as medicine.

But earlier this year, some of the leading researchers at Johns Hopkins University — people who’ve pioneered some of the highest-caliber studies on psychedelics’ therapeutic mental health potential — suggested that’s what should happen for a drug derived from magic mushrooms.See the rest of the story at Business Insider

NOW WATCH: 3 compelling reasons why we haven’t found aliens yet

See Also:

A DNA test offered by Albertsons claims to tell you which antidepressant is best for you, but scientists say it’s not worth the moneyTherapy in a pill: Breaking down the science behind the strange, surreal world of Netflix’s “Maniac”What ayahuasca — Silicon Valley’s latest drug of choice — does to your brain and body

SEE ALSO: A drug derived from marijuana has triggered the first federal shift on cannabis in half a century, and experts predict an avalanche effect

DON’T MISS: The DEA’s surprising shift on marijuana could keep a booming $1 billion industry in check, experts say

Read more: feedproxy.google.com